124 related articles for article (PubMed ID: 6750020)
41. Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens.
Zwick C; Preuss KD; Kubuschok B; Held G; Ahlgrimm M; Bittenbring J; Schubert J; Neumann F; Pfreundschuh M
Ann Hematol; 2009 Oct; 88(10):999-1003. PubMed ID: 19238384
[TBL] [Abstract][Full Text] [Related]
42. [Detection of serum anti-p53 antibodies in patients with various types of cancer].
Sakai H
Rinsho Byori; 2002 Jan; 50(1):90-2. PubMed ID: 11871143
[TBL] [Abstract][Full Text] [Related]
43. Harnessing immunity for cancer marker discovery.
Hanash S
Nat Biotechnol; 2003 Jan; 21(1):37-8. PubMed ID: 12511908
[No Abstract] [Full Text] [Related]
44. [Contemporary molecular-biological methods of cancer diagnosis and monitoring based on the humoral immune response to tumor-associated antigens].
Shebzukhov IuV; Belousov PV; Khlgatian SV; Sazykin AIu; Kuprash DV; Nedospasov SA
Mol Gen Mikrobiol Virusol; 2007; (2):3-6. PubMed ID: 17600920
[TBL] [Abstract][Full Text] [Related]
45. Alpha1,2fucosylation is a superior predictor of postoperative prognosis for colorectal cancer compared with blood group A, B, or sialyl Lewis X antigen generated within colorectal tumor tissues.
Tsuboi K; Asao T; Ide M; Hashimoto S; Noguchi K; Kominato Y; Saniabadi AR; Kuwano H; Yazawa S
Ann Surg Oncol; 2007 Jun; 14(6):1880-9. PubMed ID: 17375356
[TBL] [Abstract][Full Text] [Related]
46. Tumor markers of the central nervous system: biological basis and clinical relevance.
Birkmayer GD
Cancer Detect Prev; 1983; 6(1-2):317-24. PubMed ID: 6883389
[TBL] [Abstract][Full Text] [Related]
47. Discrimination of breast cancer by anti-malignin antibody serum test in women undergoing biopsy.
Harman SM; Gucciardo F; Heward CB; Granstrom P; Barclay-White B; Rogers LW; Ibarra JA
Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2310-5. PubMed ID: 16214910
[TBL] [Abstract][Full Text] [Related]
48. [Marker substances in the diagnosis of malignant diseases].
Gericke D; Drahovsky D
MMW Munch Med Wochenschr; 1983 Oct; 125(40):865-7. PubMed ID: 6415469
[No Abstract] [Full Text] [Related]
49. Serum MAGE-4 protein in ovarian cancer patients.
Kawagoe H; Yamada A; Matsumoto H; Ito M; Ushijima K; Nishida T; Yakushiji M; Itoh K
Gynecol Oncol; 2000 Mar; 76(3):336-9. PubMed ID: 10684707
[TBL] [Abstract][Full Text] [Related]
50. The prognostic value of immunofluorescence from oral swabs in patients with tonsillar carcinoma.
Mang WL; Hammer C
J Med; 1981; 12(6):447-53. PubMed ID: 7033427
[TBL] [Abstract][Full Text] [Related]
51. Tumor-associated antigens and biomarkers in cancer and immune therapy.
Malyankar UM
Int Rev Immunol; 2007; 26(3-4):223-47. PubMed ID: 17558745
[TBL] [Abstract][Full Text] [Related]
52. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33.
Ritter G; Cohen LS; Williams C; Richards EC; Old LJ; Welt S
Cancer Res; 2001 Sep; 61(18):6851-9. PubMed ID: 11559561
[TBL] [Abstract][Full Text] [Related]
53. Use of the antibody-dependent cellular cytotoxicity test to detect antibodies in sera of breast cancer patients.
Plain MJ; Whitehead RH; Jose DG
J Natl Cancer Inst; 1981 Apr; 66(4):619-24. PubMed ID: 7014964
[TBL] [Abstract][Full Text] [Related]
54. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
55. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth.
Bei R; Masuelli L; Palumbo C; Modesti M; Modesti A
Cancer Lett; 2009 Aug; 281(1):8-23. PubMed ID: 19091462
[TBL] [Abstract][Full Text] [Related]
56. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
57. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.
Zhang JY; Casiano CA; Peng XX; Koziol JA; Chan EK; Tan EM
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):136-43. PubMed ID: 12582023
[TBL] [Abstract][Full Text] [Related]
58. Monoclonal antibodies to detect breast cancer cells in bone marrow.
Diel IJ; Kaufmann M; Costa SD; Bastert G
Important Adv Oncol; 1994; ():143-64. PubMed ID: 8206487
[No Abstract] [Full Text] [Related]
59. Immune monitoring of cancer patients undergoing experimental immunotherapy.
Shankar G; Salgaller ML
Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653
[TBL] [Abstract][Full Text] [Related]
60. Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer.
Battaglia F; Scambia G; Panici PB; Castelli M; Ferrandina G; Foti E; Amoroso M; D'Andrea G; Mancuso S
Gynecol Oncol; 1994 May; 53(2):176-82. PubMed ID: 8188076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
